Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Triamcinolone acetonide
Drug ID BADD_D02272
Description Triamcinolone is a corticosteroid used to treat various inflammatory conditions in the body from allergic rhinitis to acute exacerbations of multiple sclerosis.[L8255] Triamcinolone can be used as a one time adjunct treatment of osteoarthritic knee pain,[L8264] or first line as a topical treatment of corticosteroid responsive dermatoses.[L8249] Triamcinolone is more commonly seen in the forms triamcinolone hexacetonide, triamcinolone acetonide, and triamcinolone diacetate.[L8246,L8249,L8252,L8255,L8258,L8261,L8264] Triamcinolone was granted FDA approval on 3 December 1957.[L8243] In October 2021, a suspension of triamcinolone acetonide was approved for suprachoroidal injection - the first suprachoroidal injection to receive FDA approval[L38973] - for the treatment of patients with macular edema associated with uveitis.[L38963]
Indications and Usage Triamcinolone hexacetonide injections are indicated for intralesional administration in alopecia areata, discoid lupus erythematosus, keloids, and necrobiosis lipoidica diabeticorum.[L8246] This formulation can also be used for localized hypertrophic infiltrated inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus, and psoriatic plaques.[L8246] Triamcinolone acetonide spray and cream are indicated for the treatment of inflammatory and pruritic manifestations of corticosteroid responsive dermatoses.[L8249,L8258] A triamcinolone acetonide 10mg/mL or 40mg/mL injection is indicated intra-articularly for acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, and synovitis of osteoarthritis.[L8252,L8255] The same 10mg/mL injection is indicated by the intralesional route for the treatment of alopecia areata, discoid lupus erythematosus, keloids, necrobiosis lipoidica diabeticorum, and tumors of an aponeurosis or tendon.[L8252] This formulation can also be used for localized hypertrophic infiltrated inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus, and psoriatic plaques.[L8252] The 40mg/mL injection is indicated intramuscularly for controlling severe allergic conditions such as asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity, perennial or seasonal allergic rhinitis, serum sickness, and transfusion reactions; treatment of bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, Stevens-Johnson syndrome, congenital adrenal hyperplasia, hypercalcemia in cancer, nonsuppurative thyroiditis, autoimmune hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, secondary thrombocytopenia, trichinosis, tuberculous meningitis, acute exacerbations of multiple sclerosis or cerebral edema, sympathetic ophthalmia, temporal arteritis, uveitis, ocular inflammation, berylliosis, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis, dermatomyositis, polymyositis, and systemic lupus erythematosus; adjunct treatment of adrenocortical insufficiency, regional enteritis, ulcerative colitis, fulminating or disseminated pulmonary tuberculosis, acute gouty arthritis, acute rheumatic carditis, ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis; palliative management of leukemia and lymphoma; induction of diuresis or remission of proteinuria in idiopathic nephrotic syndrome or lupus erythematosus.[L8255] A triamcinolone intravitreal injection is indicated for the treatment of sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions.[L8261] The intravitreal injection is also used for visualization during vitrectomy.[L8261] An extended release suspension is indicated intra-articularly for management of pain in osteoarthritis of the knee.[L8264] A triamcinolone acetonide suspension for injection into the suprachoroidal space is indicated for the treatment of macular edema associated with uveitis.[L38963]
Marketing Status approved; vet_approved
ATC Code D07AB09; D07XB02; C05AA12; S01BA05; R03BA06; R01AD11; A01AC01; H02AB08
DrugBank ID DB00620
KEGG ID D00983
MeSH ID D014222
PubChem ID 6436
TTD Drug ID Not Available
NDC Product Code 76420-085; 76420-222; 81298-5781; 46439-8703; 41167-5800; 41250-443; 0168-0006; 50090-3802; 51672-1335; 0316-0165; 61919-619; 63629-8782; 63629-8785; 64380-800; 67457-621; 68071-2743; 70518-2403; 70518-3373; 71205-009; 71205-033; 0713-0226; 0713-0229; 0713-0655; 0003-0293; 76003-1145; 82298-123; 16714-987; 36800-621; 45865-898; 50090-2244; 51672-1282; 53002-9770; 63629-8783; 68071-1872; 68788-7501; 68788-8350; 70121-1653; 70121-1654; 70752-140; 71205-108; 71205-627; 72162-1832; 81298-5783; 0003-0494; 49452-7900; 51552-0033; 16714-150; 33342-333; 41163-443; 0168-0002; 44118-711; 45802-045; 50090-0293; 50090-0295; 50090-2106; 55150-384; 0316-0175; 61919-650; 63187-661; 63629-2406; 63629-8780; 63629-8784; 67877-251; 68071-2339; 68071-2736; 70121-1049; 70121-1168; 70518-2285; 55150-385; 55910-280; 59088-730; 62011-0320; 0363-0811; 63187-025; 63187-214; 63629-2407; 63629-9573; 67877-318; 68788-7797; 70121-1651; 70518-2393; 70529-048; 0703-0245; 80425-0262; 12516-1508; 12516-1509; 57582-018; 65089-0008; 71161-135; 16714-267; 30142-443; 0113-0443; 40032-097; 0168-0004; 45802-055; 50090-1444; 52817-811; 53002-9333; 63187-870; 64380-901; 64980-320; 68071-1623; 68788-7048; 71205-451; 71565-040; 72189-039; 72189-277; 0703-0243; 0713-0228; 76420-203; 51927-0306; 10631-093; 21130-443; 33342-329; 33342-332; 35573-404; 45802-063; 45802-064; 50090-6533; 63629-8708; 64380-870; 67457-622; 67457-623; 68071-2294; 68788-8386; 70121-1657; 70752-130; 46439-8730; 62991-1156; 16714-985; 24470-922; 33342-331; 45802-817; 49035-443; 50090-0362; 50090-5980; 51672-1267; 0316-0170; 61919-594; 63629-9574; 64380-802; 67877-317; 68462-131; 68788-8356; 68788-8457; 70752-129; 0713-0676; 12516-1510; 67438-045; 24208-040; 42571-385; 0168-0003; 45802-049; 45802-065; 50090-0163; 50090-0256; 51672-1284; 53002-9120; 63187-053; 68462-797; 70000-0204; 70121-1655; 70518-3689; 70677-1023; 71205-038; 46439-8742; 49076-6701; 52128-173; 52945-068; 73301-011; 76420-162; 11673-717; 16714-140; 16714-268; 16714-986; 30142-813; 0168-0005; 45802-054; 51862-290; 53002-9334; 59088-733; 59779-746; 63187-495; 63629-8778; 63629-8781; 63981-443; 64380-801; 64980-429; 68788-7814; 70121-1169; 70518-2938; 71205-124; 72288-443; 0703-0241; 0713-0225; 74157-901; 76420-220; 0003-0315; 81298-5785; 22552-0032; 60722-3012; 16714-130; 33342-327; 46122-385; 50090-2658; 50090-6547; 53002-0151; 63629-8456; 63629-8707; 63629-8779; 63629-8841; 64380-871; 68462-798; 68788-7506; 70121-1652; 70518-1094; 71428-010; 0065-0543; 38779-0011; 51927-0134; 63275-9943; 33342-328; 37808-443; 45802-109; 46287-010; 49999-150; 50090-6211; 53002-9331
UNII F446C597KA
Synonyms Triamcinolone Acetonide | Acetonide, Triamcinolone | Cinonide | Tricort-40 | Tricort 40 | Tricort40 | Kenalog | Kenalog 40 | Azmacort | Kenacort A
Chemical Information
Molecular Formula C24H31FO6
CAS Registry Number 76-25-5
SMILES CC1(OC2CC3C4CCC5=CC(=O)C=CC5(C4(C(CC3(C2(O1)C(=O)CO)C)O)F)C)C
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Hypokinesia17.01.02.009--Not Available
Hypopituitarism05.03.02.001--
Hypopyon11.01.06.009; 06.04.10.004--Not Available
Hypotension24.06.03.002--
Impaired healing08.03.02.001--Not Available
Increased appetite08.01.09.027; 14.03.01.003--Not Available
Increased insulin requirement14.06.01.006; 05.06.01.006--Not Available
Increased tendency to bruise23.06.01.009; 01.01.03.005; 24.07.06.012--Not Available
Infection11.01.08.002--Not Available
Infection susceptibility increased11.01.08.004; 10.02.01.046--Not Available
Influenza22.07.02.001; 11.05.03.001--Not Available
Injection site atrophy12.07.03.022; 08.02.03.0220.001497%Not Available
Injection site bruising24.07.06.017; 23.03.11.015; 12.07.03.042; 08.02.03.0420.000139%Not Available
Injection site erythema23.03.06.015; 12.07.03.001; 08.02.03.0010.000093%Not Available
Injection site extravasation12.07.03.002; 08.02.03.0020.000107%Not Available
Injection site haemorrhage12.07.03.005; 24.07.01.010; 08.02.03.0050.000087%Not Available
Injection site induration12.07.03.007; 08.02.03.0070.000139%Not Available
Injection site inflammation12.07.03.009; 08.02.03.0080.000027%Not Available
Injection site irritation12.07.03.027; 08.02.03.0270.000060%Not Available
Injection site necrosis12.07.03.020; 08.02.03.0200.000120%Not Available
Injection site pain12.07.03.011; 08.02.03.0100.000874%Not Available
Injection site rash23.03.13.010; 12.07.03.032; 08.02.03.0320.000279%Not Available
Injection site reaction12.07.03.015; 08.02.03.0140.000625%
Injection site ulcer23.07.03.012; 12.07.03.017; 08.02.03.0160.000060%Not Available
Injury12.01.08.004--Not Available
Insomnia19.02.01.002; 17.15.03.002--
Intestinal perforation07.04.06.0020.000041%Not Available
Intracranial pressure increased17.07.02.002--Not Available
Intraocular pressure increased13.07.04.002--Not Available
Irritability19.04.02.013; 08.01.03.011--
The 6th Page    First    Pre   6 7 8 9 10    Next   Last    Total 16 Pages